This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Celsion announces TARDOX study combining ThermoDox and focused ultrasound to tackle cancers

Celsion Corporation has launched a clinical trial, supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), to study the effectiveness of combining cancer drug ThermoDox with focused ultrasound to treat a range of tumours, including liver cancer.

For the full story on Oxford Biomedical Research Centre website